10 / 31
Page 42
Notes:
conference
series
.com
Volume 6, Issue 5 (Suppl)
OMICS J Radiol, an open access journal
ISSN: 2167-7964
Radiology and Oncology 2017
October 19-20, 2017
World Congress on
October 19-20, 2017 | New York, USA
Radiology and Oncology
Survivin-targeted strategy for cancer treatment
Ren Chongxi
Hebei Medical University, China
S
urvivin, a new member of inhibitors of apoptosis proteins (IAP) family, regulates the essential cellular processes, including
inhibition of cell apoptosis and autophagic cell death, promotion of cell proliferation and tumor stromal angiogenesis. Survivin
is undetectable in most terminally differentiated tissues, but upregulated in almost all types of human malignancies and its aberrant
overexpression positively correlates with chemotherapy resistance, increased tumor recurrence and shortened patient survival.
Because of its key role in tumor formation and development, Survivin is considered as an ideal target for anticancer treatment.This
review discussed the molecular function of Survivin, relationship between Survivin and cancer biological characteristics, as well as
the research progress of cancer therapy by targeting Survivin.
Biography
Ren Chongxi graduated from Hebei Medical University and completed his MD from QingDao University School of Medicine. He is the Director of Department of Surgical
Oncology, Hebei Medical University. He has published more than 20 papers in reputed journals and has been serving as an Editorial Board Member of repute.
rcxvip@outlook.comRen Chongxi, OMICS J Radiol 2017, 6:5 (Suppl)
DOI: 10.4172/2167-7964-C1-015